https://www.selleckchem.com/pr....oducts/brigimadlin.h
However, on an ITT basis, there was no significant difference in survival between resectable, BR-V and BR-A/LA disease (median 19 versus 15 versus 19 months; P = 0.585). On review, some 31 (44%) patients of the BR-A/LA cohort either did not receive or did not complete NAT. To realize benefits of NAT, more patients need to complete NAT and to undergo resection. Upfront resection for BR-V disease is associated with equivalent outcomes to upfront surgery for resectable disease or NAT for BR-A/LA disease. Strategies to increase the prop
Giống
Bình luận
Đăng lại
